Collabora'on between Coopera'on: Universi'es and Industry in Czech Republic. Kamil Kuča

Rozměr: px

Začít zobrazení ze stránky:

Download "Collabora'on between Coopera'on: Universi'es and Industry in Czech Republic. Kamil Kuča"

Martina Vítková
před 8 lety
Počet zobrazení:

1 Collabora'on between Coopera'on: Universi'es and Industry in Czech Republic Kamil Kuča

3 Content CTBT Coopera'on with Companies Biomedical Research Center ( spin- off )

4 CTBT

5 Hradec Kralove - Biomedicine University Hospital HK Faculty of Medicine LFHK UH HK Faculty of Military Health Sciences FVZ Pharmaceutical faculty Faf UHK Faculty of Science UHK Faculty of Informactics and Managment UHK (Biomedical Informatics Center)

6 CTBT responsible University Hospital Hradec Kralove University of Hradec Kralove Faculty of Military Health Sciences

7 TTO Call Czech Republic Project University Budget Centrum transferu biomedicínských technologií HK Fakultní nemocnice Hradec Králové Univerzita Hradec Králové Fakulta vojenského zdravotnictví Kč Centrum transferu technologií a znalosm UPa Univerzita Pardubice Kč Jihočeské Univerzitní a Akademické CTT Jihočeská univerzita v Českých Budějovicích Kč InovaNET České vysoké učení technické v Praze Kč Centrum pro inovace a transfer technologií Fyzikální ústav AV ČR, v.v.i Kč Transfer technologií na Masarykově univerzitě Masarykova univerzita Kč Centrum Transferu Technologií MENDELU Mendelova univerzita v Brně Kč Rozvoj CTT na UTB ve Zlíně Univerzita Tomáše Ba' ve Zlíně Kč Rozvoj a stabilizace systému TT VŠB- TUO Vysoká škola báňská - Technická univerzita Ostrava Kč

8 CTBT in numbers Budget Personal th. Kč % CTBT per. CTBT FTE Tech. Sc. Tech. Sc. FTE Sum % 6 5,5 11 1,2 FN HK % ,6 UHK % 1 0,5 3 0,3 FVZ 931 4% ,3 Project 100% Project Sustainability Paid by partners and CTBT income CTBT Income and partners 07/12-06/15 07/15-06/20 07/20 -?

9 CTBT goal Intellectual property, Spin-off setup, Management of service research, Searching for results which could be applied in the real praxis, PR for FN HK, UHK a FVZ UO, Making contacts with companies, Searching for reasults.

10 EVALUATION OF INTERNAL PROJECT Are in the project results which could be commercialized Discussion with scientists

11 SCIENTIST evaluavon

12 CooperaVon with Companies

13 Who is Coming? SME Universi'es Investors

14 Company request? Services Mutual research Technology agency projects Consulta'ons University Approval/Personal Approval connec'on of product with Ins'tute/Well- known Scien'sts Searching for accredited laboratories

15 Types of cooperavon Firstly as service Then mutual coopera'on - then par'cipa'on on results is expected

16 How do we get contacts? scien'fic mee'ngs friends (TTO, scien'sts, ) CTBT Web site students and employee research stay

17 What are we offering Quality scien'sts Environment - ready to work on different topics

18 Project for CooperaVon Czech technology agency Projects Pre- seed projects (MSMT)

19 Biomedical Research Center

20 History April Established à To prevent ouwlow of scien'sts (3 full posi'ons divided into 6 people) February Laboratory facility EU postdoc program started (4 full posi'ons gained) October empoyees (senior and junior scien'sts, PhD students, lab. assistants; total 3.2 posivons full/part 'me)

21 Aims " Support basic research in the Hospital (drug development, analysis, assessment etc.) " Service for the clinics and applied research (proteomics, pharmacokine8cs etc.) " EducaVon (pre and postgraduated students, interships, seminars)

22 Funding Projects: Currently solving 11 project (including internal) 6 internal coopera'ons (within Hospital) 8 external coopera'ons (in CZ) Grant agencies: Grant Agency of CZ, Grant agencies under Ministry of Health, Defence, Educa'on etc. Private sector (organic synthesis, cytotoxicity, acute toxicity etc) Incomes: " Projects (10-20% for the hospital) " Publica'ons (depending on the IF) " Services for fee " Licensing???...what we get, we need to pay back

23 Topics Představení proteomické skupiny Centra Biomedicínského Výzkum Proteomics D rug Chemical synthesis In vitro biologial assessment D eve l o p m ent In vivo assesment, toxicity Pharmacokinetics

24 DRUG DEVELOPMENT years, aprox. 1 mld USD BRC Drug discovery Preclinical Trials Clinical trials (I.- III. phase) Prac'cal use (IV. phase)

25 Pipeline for drug development CWA An'dotes Design and Synthesis In- vitro evaluavon Toxicity PharmacokineVcs In- vivo Targeted synthesis 1st selecvon 2nd selecvon Alzheimer s Vaccine Adjuvans? Drug candidates - recommendation for preclinical trials, commercialization Detergents

26 BRC - PROTEOMICS Clinical proteomics Quan'ta've and qualita've descrip'on of the protein content in the samples using LCMS ExploraVve analysis What pro'ens are in a sample?= idenvficavon What is the difference in quan''es of different proteins in a samples (treated vs non- treated group) = quanvficavon Targeted analysis I know what I m looking for and what is the level of this protein in different samples

27 Offering Services Joint research with companies Special analysis Preclinical research Products evaluation Articles for PR Consultation

28 Thank you very much for your a~en'on

Podobné dokumenty

Centrum transferu biomedicínských technologií Kamil Kuča

Centrum transferu biomedicínských technologií Kamil Kuča Fakultní nemocnice Hradec Králové Univerzita Hradec Králové Fakulta vojenského zdravotnictví Základní údaje Základní údaje o projektu Název projetu: